These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 30941424)
1. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. Tomita Y; Fukasawa S; Shinohara N; Kitamura H; Oya M; Eto M; Tanabe K; Saito M; Kimura G; Yonese J; Yao M; Uemura H Jpn J Clin Oncol; 2019 Jun; 49(6):506-514. PubMed ID: 30941424 [TBL] [Abstract][Full Text] [Related]
2. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Tomita Y; Fukasawa S; Shinohara N; Kitamura H; Oya M; Eto M; Tanabe K; Kimura G; Yonese J; Yao M; Motzer RJ; Uemura H; McHenry MB; Berghorn E; Ozono S Jpn J Clin Oncol; 2017 Jul; 47(7):639-646. PubMed ID: 28419248 [TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM; Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204 [TBL] [Abstract][Full Text] [Related]
7. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. Powles T; Burotto M; Escudier B; Apolo AB; Bourlon MT; Shah AY; Suárez C; Porta C; Barrios CH; Richardet M; Gurney H; Kessler ER; Tomita Y; Bedke J; George S; Scheffold C; Wang P; Fedorov V; Motzer RJ; Choueiri TK ESMO Open; 2024 May; 9(5):102994. PubMed ID: 38642472 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185 [TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863 [TBL] [Abstract][Full Text] [Related]
10. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. Ohyama C; Kojima T; Kondo T; Naya Y; Inoue T; Tomita Y; Eto M; Hisasue S; Uemura H; Obara W; Kikuchi E; Sharma P; Galsky MD; Siefker-Radtke A; Grossfeld G; Collette S; Gooden K; Kimura G Int J Clin Oncol; 2019 Sep; 24(9):1089-1098. PubMed ID: 31218529 [TBL] [Abstract][Full Text] [Related]
11. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data. Hinata N; Yonese J; Masui S; Nakai Y; Shirotake S; Tatsugami K; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Ochi K; Kaneko H; Uemura H Int J Clin Oncol; 2020 Aug; 25(8):1533-1542. PubMed ID: 32519026 [TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G; BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884 [TBL] [Abstract][Full Text] [Related]
14. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Escudier B; Motzer RJ; Sharma P; Wagstaff J; Plimack ER; Hammers HJ; Donskov F; Gurney H; Sosman JA; Zalewski PG; Harmenberg U; McDermott DF; Choueiri TK; Richardet M; Tomita Y; Ravaud A; Doan J; Zhao H; Hardy H; George S Eur Urol; 2017 Sep; 72(3):368-376. PubMed ID: 28410865 [TBL] [Abstract][Full Text] [Related]
15. A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). Shah R; Botteman M; Solem CT; Luo L; Doan J; Cella D; Motzer RJ Clin Genitourin Cancer; 2019 Oct; 17(5):356-365.e1. PubMed ID: 31272883 [TBL] [Abstract][Full Text] [Related]
18. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial. Oyama M; Sugiyama T; Nozawa M; Fujimoto K; Kishida T; Kimura G; Tokuda N; Hinotsu S; Shimozuma K; Akaza H; Ozono S Jpn J Clin Oncol; 2017 Jun; 47(6):551-559. PubMed ID: 28334974 [TBL] [Abstract][Full Text] [Related]
20. What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma. Klijn SL; Fenwick E; Kroep S; Johannesen K; Malcolm B; Kurt M; Kiff C; Borrill J Pharmacoeconomics; 2021 Mar; 39(3):345-356. PubMed ID: 33428174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]